ArticleDiabetes, obesity & metabolism2025

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.

Hannah Wallace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.